Responses
Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
716 Phase 2 study of the HER2-targeting TLR7/8 immune stimulating antibody conjugate (ISAC) BDC-1001 monotherapy +/- nivolumab in patients with HER2+ colorectal, endometrial, or gastroesophageal cancer
Compose a Response to This Article
Other responses
No responses have been published for this article.
